UT Health San Antonio MD Anderson Cancer Center (Mays Cancer Center)
Welcome,         Profile    Billing    Logout  
 8 Trials 
39 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Brenner, Andrew
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
NCT03032484: TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma

Completed
2
25
US
Bevacizumab, Avastin, TVB-2640
The University of Texas Health Science Center at San Antonio
Astrocytoma
04/20
04/21
SURVIVE, NCT05163080: SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

Active, not recruiting
2
247
US
SurVaxM
MimiVax, LLC, Translational Drug Development, Merit
Newly Diagnosed Glioblastoma
08/24
08/24
NCT04559230: Sacituzumab Govitecan in Recurrent Glioblastoma

Recruiting
2
40
US
Sacituzumab Govitecan
The University of Texas Health Science Center at San Antonio
Glioblastoma
02/26
08/26
S2007, NCT04647916: Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Active, not recruiting
2
44
US
Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU-132, RS7-SN38, Sacituzumab Govitecan-hziy, Trodelvy
SWOG Cancer Research Network, National Cancer Institute (NCI), Gilead Sciences
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
12/27
12/28
BPM31510IV-11, NCT04752813: A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)

Recruiting
2
50
US
BPM31510, Vitamin K1, Temozolomide (TMZ), Radiation
BPGbio, BPGbio
Glioblastoma, Glioblastoma Multiforme
09/25
12/25
ReSPECT-GBM, NCT01906385: Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

Recruiting
1/2
55
US
Rhenium Liposome Treatment, Rhenium-186 NanoLiposome
Plus Therapeutics, National Cancer Institute (NCI)
Glioma
12/25
12/25
ELECTRA, NCT05386108 / 2022-001087-10: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Recruiting
1/2
68
Europe, US, RoW
Elacestrant, Elacestrant dihydrochloride, RAD-1901, ER-306323, Orserdu, Abemaciclib, Verzenio
Stemline Therapeutics, Inc., Stemline Therapeutics, Inc
Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
12/25
12/25
NCT02538484: Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects

Completed
1
24
US
Letrozole, Femara, Fish Oil, Omega-3
The University of Texas Health Science Center at San Antonio
Breast Cancer
03/20
03/20
NCT03995706: Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0

Completed
1
26
US
Sacituzumab Govitecan
The University of Texas Health Science Center at San Antonio, Gilead Sciences
Glioblastoma
06/22
03/24
NCT05460507: Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment

Recruiting
1
40
US
Retreatment Rhenium Liposome, Rhenium-186 NanoLiposome
Plus Therapeutics
Glioma
03/28
03/28
ReSPECT-LM, NCT05034497: Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

Active, not recruiting
1
18
US
186RNL, Rhenium-186 NanoLiposome
Plus Therapeutics
Leptomeningeal Metastasis
12/25
06/26
TRIDENT, NCT04471844: Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM

Active, not recruiting
N/A
982
Europe, Canada, Japan, US, RoW
Optune®
NovoCure Ltd.
Glioblastoma Multiforme
01/26
01/26
NCT03115333: DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma

Recruiting
N/A
146
US
Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, DSC-MRI, Dynamic Susceptibility Contrast-Enhanced MRI, DYNAMIC SUSCEPTIBILITY-CONTRAST MRI
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Gliosarcoma, Recurrent Glioblastoma
09/25
05/27
Goodwin, Epp
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Jan 2024 - Dec 2024: Approval for myelofibrosis
Hourglass Jul 2024 - Dec 2024 : Regulatory submission in EU for 1L myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Completion of P2b trial for JIA
Feb 2024 - Feb 2024: Exclusivity expiry in US
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Recruiting
3
750
Europe, US
Placebo, GLSI-100
Greenwich LifeSciences, Inc.
Breast Cancer
12/26
12/26
NCT04081220: Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2

Active, not recruiting
2
9
US
IMG-7289, LSD1 inhibitor
The University of Texas Health Science Center at San Antonio, Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Thrombocythemia, Essential
12/23
01/25
NCT04559230: Sacituzumab Govitecan in Recurrent Glioblastoma

Recruiting
2
40
US
Sacituzumab Govitecan
The University of Texas Health Science Center at San Antonio
Glioblastoma
02/26
08/26
NCT03037437: Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer

Active, not recruiting
2
64
US
Sorafenib (SOR), Nexavar, Hydroxychloroquine (HCQ), Plaquenil
The University of Texas Health Science Center at San Antonio
Hepatocellular Cancer
06/25
06/25
NCT04291105: Phase 2 Trial of Voyager V1 in Combination with Cemiplimab in Cancer Patients

Recruiting
2
87
US, RoW
VV1, VSV-IFNβ-NIS, Voyager V1, VV1, Cemiplimab, Libtayo
Vyriad, Inc., Regeneron Pharmaceuticals
Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
06/25
12/25
NCT04863950: Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma

Recruiting
2
25
US
Lomustine, Gleostine, Imipramine Hydrochloride, Trofranil
The University of Texas Health Science Center at San Antonio
Glioblastoma
02/26
09/26
PERSEVERE, NCT04849364: Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

Active, not recruiting
2
197
US
Capecitabine, Xeloda, Talazoparib, Talzenna, Pembrolizumab, Keytruda, Inavolisib, GDC-0077
Bryan Schneider, MD, Genentech, Inc., Pfizer, Foundation Medicine, Indiana University, Vera Bradley Foundation for Breast Cancer Research
Breast Cancer, Triple Negative Breast Cancer
01/29
01/34
NCT06516887: Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma

Recruiting
1/2
44
US
bemcentinib, pacritinib
The University of Texas Health Science Center at San Antonio, National Cancer Institute (NCI)
Advanced Lung Adenocarcinoma
09/27
09/27
ReSPECT-GBM, NCT01906385: Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

Recruiting
1/2
55
US
Rhenium Liposome Treatment, Rhenium-186 NanoLiposome
Plus Therapeutics, National Cancer Institute (NCI)
Glioma
12/25
12/25
SKYBRIDGE, NCT05652686: A Study of Peluntamig (PT217) in Patients with Neuroendocrine Carcinomas Expressing DLL3 (the Study)

Recruiting
1/2
203
US
Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel., Atezolizumab
Phanes Therapeutics, Hoffmann-La Roche
Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), Neuroendocrine Carcinomas (NEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
12/27
08/28
NCT05440708: A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Recruiting
1/2
178
US
TTI-101, Pembrolizumab, Keytruda®, Atezolizumab, Tecentriq®, Bevacizumab, Avastin®
Tvardi Therapeutics, Incorporated
Hepatocellular Carcinoma
06/26
06/27
KEYNOTE-D88, NCT05572684: A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors

Active, not recruiting
1/2
97
US
NC410, pembrolizumab, KEYTRUDA®
NextCure, Inc., Merck Sharp & Dohme LLC
Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer, Esophageal Cancer, Endometrial Cancer, Head Neck Cancer, Cervical Cancer, Lung Cancer
07/25
11/25
NCT02538484: Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects

Completed
1
24
US
Letrozole, Femara, Fish Oil, Omega-3
The University of Texas Health Science Center at San Antonio
Breast Cancer
03/20
03/20
NCT03893682: A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Terminated
1
36
US
CG-806, Luxeptinib
Aptose Biosciences Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma
05/24
05/24
NCT06246786: Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer)

Recruiting
1
24
US
Cyclosporin A, CsA
Virginia G. Kaklamani
Triple Negative Breast Cancer, DNA Damage Repair Deficiency
07/26
07/27
LNCB74-01, NCT06774963: A Phase 1 Study of LNCB74 in Advanced Solid Tumors

Recruiting
1
145
US
LNCB74
NextCure, Inc., LigaChem Biosciences, Inc.
Ovarian Cancer, Breast Cancer, Endometrial Cancer, Biliary Tract Cancer, Non-Small Cell Lung Cancer, Advanced or Metastatic Solid Tumors
12/26
12/26
NCT06609005: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients with Advanced Metastatic Castration Resistant Prostate Cancer

Recruiting
1
66
US, RoW
INV-9956
Shenzhen Ionova Life Sciences Co., Ltd.
Advanced Metastatic Castration Resistant Prostate Cancer
04/26
03/27
ReSPECT-LM, NCT05034497: Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

Active, not recruiting
1
18
US
186RNL, Rhenium-186 NanoLiposome
Plus Therapeutics
Leptomeningeal Metastasis
12/25
06/26
NCT04784689: Host Immune Response to Novel RNA COVID-19 Vaccination

Completed
N/A
50
US
COVID-19 Vaccine
The University of Texas Health Science Center at San Antonio
COVID-19 Vaccine, Cancer
05/22
05/22
NCT03655015: Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer

Recruiting
N/A
150
US
Lung Tumor Resection
The University of Texas Health Science Center at San Antonio, National Cancer Institute (NCI)
Lung Neoplasm
12/28
12/29
NCT04531709: Financial Toxicity and Quality of Life in Patients With TGCT

Recruiting
N/A
30
US
Comprehensive Score for financial toxicity (COST), Functional Assessment of Cancer Therapy: General (FACT-G), EORTC QLQ C-30, EORTC QLQ-TC26.
The University of Texas Health Science Center at San Antonio
Testicular Neoplasm
04/25
12/25
NCT05248256: Vertebral Marrow Attention Trial (VMAT)

Completed
N/A
12
US
Evidence-based radiation dose limitation to the vertebral bone marrow
The University of Texas Health Science Center at San Antonio
Lung Cancer
07/24
09/24
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting
N/A
30000
Europe, Canada, US, RoW
MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint
Agendia
Breast Cancer
04/37
12/37
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Brenner, Andrew
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
NCT03032484: TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma

Completed
2
25
US
Bevacizumab, Avastin, TVB-2640
The University of Texas Health Science Center at San Antonio
Astrocytoma
04/20
04/21
SURVIVE, NCT05163080: SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

Active, not recruiting
2
247
US
SurVaxM
MimiVax, LLC, Translational Drug Development, Merit
Newly Diagnosed Glioblastoma
08/24
08/24
NCT04559230: Sacituzumab Govitecan in Recurrent Glioblastoma

Recruiting
2
40
US
Sacituzumab Govitecan
The University of Texas Health Science Center at San Antonio
Glioblastoma
02/26
08/26
S2007, NCT04647916: Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Active, not recruiting
2
44
US
Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU-132, RS7-SN38, Sacituzumab Govitecan-hziy, Trodelvy
SWOG Cancer Research Network, National Cancer Institute (NCI), Gilead Sciences
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
12/27
12/28
BPM31510IV-11, NCT04752813: A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)

Recruiting
2
50
US
BPM31510, Vitamin K1, Temozolomide (TMZ), Radiation
BPGbio, BPGbio
Glioblastoma, Glioblastoma Multiforme
09/25
12/25
ReSPECT-GBM, NCT01906385: Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

Recruiting
1/2
55
US
Rhenium Liposome Treatment, Rhenium-186 NanoLiposome
Plus Therapeutics, National Cancer Institute (NCI)
Glioma
12/25
12/25
ELECTRA, NCT05386108 / 2022-001087-10: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Recruiting
1/2
68
Europe, US, RoW
Elacestrant, Elacestrant dihydrochloride, RAD-1901, ER-306323, Orserdu, Abemaciclib, Verzenio
Stemline Therapeutics, Inc., Stemline Therapeutics, Inc
Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
12/25
12/25
NCT02538484: Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects

Completed
1
24
US
Letrozole, Femara, Fish Oil, Omega-3
The University of Texas Health Science Center at San Antonio
Breast Cancer
03/20
03/20
NCT03995706: Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0

Completed
1
26
US
Sacituzumab Govitecan
The University of Texas Health Science Center at San Antonio, Gilead Sciences
Glioblastoma
06/22
03/24
NCT05460507: Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment

Recruiting
1
40
US
Retreatment Rhenium Liposome, Rhenium-186 NanoLiposome
Plus Therapeutics
Glioma
03/28
03/28
ReSPECT-LM, NCT05034497: Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

Active, not recruiting
1
18
US
186RNL, Rhenium-186 NanoLiposome
Plus Therapeutics
Leptomeningeal Metastasis
12/25
06/26
TRIDENT, NCT04471844: Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM

Active, not recruiting
N/A
982
Europe, Canada, Japan, US, RoW
Optune®
NovoCure Ltd.
Glioblastoma Multiforme
01/26
01/26
NCT03115333: DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma

Recruiting
N/A
146
US
Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, DSC-MRI, Dynamic Susceptibility Contrast-Enhanced MRI, DYNAMIC SUSCEPTIBILITY-CONTRAST MRI
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Gliosarcoma, Recurrent Glioblastoma
09/25
05/27
Goodwin, Epp
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Jan 2024 - Dec 2024: Approval for myelofibrosis
Hourglass Jul 2024 - Dec 2024 : Regulatory submission in EU for 1L myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Completion of P2b trial for JIA
Feb 2024 - Feb 2024: Exclusivity expiry in US
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Recruiting
3
750
Europe, US
Placebo, GLSI-100
Greenwich LifeSciences, Inc.
Breast Cancer
12/26
12/26
NCT04081220: Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2

Active, not recruiting
2
9
US
IMG-7289, LSD1 inhibitor
The University of Texas Health Science Center at San Antonio, Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Thrombocythemia, Essential
12/23
01/25
NCT04559230: Sacituzumab Govitecan in Recurrent Glioblastoma

Recruiting
2
40
US
Sacituzumab Govitecan
The University of Texas Health Science Center at San Antonio
Glioblastoma
02/26
08/26
NCT03037437: Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer

Active, not recruiting
2
64
US
Sorafenib (SOR), Nexavar, Hydroxychloroquine (HCQ), Plaquenil
The University of Texas Health Science Center at San Antonio
Hepatocellular Cancer
06/25
06/25
NCT04291105: Phase 2 Trial of Voyager V1 in Combination with Cemiplimab in Cancer Patients

Recruiting
2
87
US, RoW
VV1, VSV-IFNβ-NIS, Voyager V1, VV1, Cemiplimab, Libtayo
Vyriad, Inc., Regeneron Pharmaceuticals
Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
06/25
12/25
NCT04863950: Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma

Recruiting
2
25
US
Lomustine, Gleostine, Imipramine Hydrochloride, Trofranil
The University of Texas Health Science Center at San Antonio
Glioblastoma
02/26
09/26
PERSEVERE, NCT04849364: Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

Active, not recruiting
2
197
US
Capecitabine, Xeloda, Talazoparib, Talzenna, Pembrolizumab, Keytruda, Inavolisib, GDC-0077
Bryan Schneider, MD, Genentech, Inc., Pfizer, Foundation Medicine, Indiana University, Vera Bradley Foundation for Breast Cancer Research
Breast Cancer, Triple Negative Breast Cancer
01/29
01/34
NCT06516887: Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma

Recruiting
1/2
44
US
bemcentinib, pacritinib
The University of Texas Health Science Center at San Antonio, National Cancer Institute (NCI)
Advanced Lung Adenocarcinoma
09/27
09/27
ReSPECT-GBM, NCT01906385: Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

Recruiting
1/2
55
US
Rhenium Liposome Treatment, Rhenium-186 NanoLiposome
Plus Therapeutics, National Cancer Institute (NCI)
Glioma
12/25
12/25
SKYBRIDGE, NCT05652686: A Study of Peluntamig (PT217) in Patients with Neuroendocrine Carcinomas Expressing DLL3 (the Study)

Recruiting
1/2
203
US
Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel., Atezolizumab
Phanes Therapeutics, Hoffmann-La Roche
Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), Neuroendocrine Carcinomas (NEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
12/27
08/28
NCT05440708: A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Recruiting
1/2
178
US
TTI-101, Pembrolizumab, Keytruda®, Atezolizumab, Tecentriq®, Bevacizumab, Avastin®
Tvardi Therapeutics, Incorporated
Hepatocellular Carcinoma
06/26
06/27
KEYNOTE-D88, NCT05572684: A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors

Active, not recruiting
1/2
97
US
NC410, pembrolizumab, KEYTRUDA®
NextCure, Inc., Merck Sharp & Dohme LLC
Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer, Esophageal Cancer, Endometrial Cancer, Head Neck Cancer, Cervical Cancer, Lung Cancer
07/25
11/25
NCT02538484: Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects

Completed
1
24
US
Letrozole, Femara, Fish Oil, Omega-3
The University of Texas Health Science Center at San Antonio
Breast Cancer
03/20
03/20
NCT03893682: A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Terminated
1
36
US
CG-806, Luxeptinib
Aptose Biosciences Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma
05/24
05/24
NCT06246786: Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer)

Recruiting
1
24
US
Cyclosporin A, CsA
Virginia G. Kaklamani
Triple Negative Breast Cancer, DNA Damage Repair Deficiency
07/26
07/27
LNCB74-01, NCT06774963: A Phase 1 Study of LNCB74 in Advanced Solid Tumors

Recruiting
1
145
US
LNCB74
NextCure, Inc., LigaChem Biosciences, Inc.
Ovarian Cancer, Breast Cancer, Endometrial Cancer, Biliary Tract Cancer, Non-Small Cell Lung Cancer, Advanced or Metastatic Solid Tumors
12/26
12/26
NCT06609005: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients with Advanced Metastatic Castration Resistant Prostate Cancer

Recruiting
1
66
US, RoW
INV-9956
Shenzhen Ionova Life Sciences Co., Ltd.
Advanced Metastatic Castration Resistant Prostate Cancer
04/26
03/27
ReSPECT-LM, NCT05034497: Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

Active, not recruiting
1
18
US
186RNL, Rhenium-186 NanoLiposome
Plus Therapeutics
Leptomeningeal Metastasis
12/25
06/26
NCT04784689: Host Immune Response to Novel RNA COVID-19 Vaccination

Completed
N/A
50
US
COVID-19 Vaccine
The University of Texas Health Science Center at San Antonio
COVID-19 Vaccine, Cancer
05/22
05/22
NCT03655015: Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer

Recruiting
N/A
150
US
Lung Tumor Resection
The University of Texas Health Science Center at San Antonio, National Cancer Institute (NCI)
Lung Neoplasm
12/28
12/29
NCT04531709: Financial Toxicity and Quality of Life in Patients With TGCT

Recruiting
N/A
30
US
Comprehensive Score for financial toxicity (COST), Functional Assessment of Cancer Therapy: General (FACT-G), EORTC QLQ C-30, EORTC QLQ-TC26.
The University of Texas Health Science Center at San Antonio
Testicular Neoplasm
04/25
12/25
NCT05248256: Vertebral Marrow Attention Trial (VMAT)

Completed
N/A
12
US
Evidence-based radiation dose limitation to the vertebral bone marrow
The University of Texas Health Science Center at San Antonio
Lung Cancer
07/24
09/24
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting
N/A
30000
Europe, Canada, US, RoW
MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint
Agendia
Breast Cancer
04/37
12/37

Download Options